Avirmax Inc. Announces Publication in Genetic Engineering & Biotechnology News
-Overcoming Biosafety Challenges posed by Viral Vectors through Bac-to-AAV, 2D-HPLC, QbD, LC-MS/MS, and other Technologies
Hayward, CA [December 9, 2021]—Dr. Shawn (Shengjiang) Liu, President and CEO of Avirmax, Inc., in San Francisco Bay Area, today announced technical contributions and collaboration with Dr. Kathy Liszewski, Assistant Professor of Medicine at Washington University School of Medicine in St. Louis.
The full article is titled, “Extending Biosafety Testing to Gene Therapy Products,” and is available online at: https://www.genengnews.com/topics/bioprocessing/extending-biosafety-testing-to-gene-therapy-products/. Dr. Liu highlighted the pathogen safety assurance provided by Sf9 cell culture systems compared to more common human or other mammalian systems to develop and manufacture adeno-associated virus (AAV) vector-mediated biotherapeutics.
In order to achieve a robust biosafety profile, the industry must combine goals related to predictable processes and novel advances in technology to address this evolving field. While gene therapy vector production is still in its infancy in terms of the technologies, Dr. Liu is optimistic the industry will solve its challenges, commenting “Since the first recombinant protein that was approved for human use, there has been no single case of viral infection/transmission caused by a therapeutic product manufactured using recombinant technology. I believe this will be true for gene therapy vector production”.
About Avirmax, Inc.
Avirmax, Inc. based in San Francisco Bay Area, is dedicated to innovate, develop and manufacture adeno-associated virus (AAV) vector mediated biotherapeutics for Ocular Indications using its proprietary protein therapeutics and BAC-to-AAV technologies. Avirmax Adeno-associated Vector Innovation Platform (AAVIP), enables us to become a “powerhouse” of rAAV therapeutics for its very infectious AAV vectors with high titers at production and enhanced expression of gene of interest (GOI) in target cells. Our ultimate goal is to deliver patients with the effective, safe, long-acting AAV-mediated biotherapeutics at the most affordable and accessible manner.
Avirmax, Inc is dedicated to innovate and develop novel technologies to address current challenges in viral vector production based on its state-of-the-art AAV bioprocess technologies in combination with Virovek’s BAC-to-AAV insect system. Avirmax has established robust rAAV vector production technologies for small and large-scale applications using Sf9-Baculovirus system.
Find out more information on our website www.avirmax.com
Avirmax, Inc. Forward-Looking Statements
This press release contains forward-looking statements based on current assumptions and forecasts made by Avirmax management. These forward-looking statements, including statements relating to expectations, plans and prospects regarding the success of formal content included or assumed from presentations regarding new discoveries and advances in viral vector development and manufacturing as an opportunity to advance innovation in the hope of generating new therapies. Although we believe our plans, intentions, expectations, strategies and prospects as reflected in or suggested by these forward-looking statements are reasonable, we can give no assurance that the plans, intentions, expectations or strategies will be attained or achieved. Furthermore, actual results may differ materially from those described in the forward-looking statements and will be affected by a number of risks, uncertainties and assumptions, including but not limited to, the success of our development and manufacturing technologies to produce therapeutics and the success of our operations. Moreover, we operate in a very competitive and rapidly changing environment in which new risks emerge from time to time. Except as required by applicable law, we assume no obligation to update publicly any forward-looking statements, whether as a result of new information, future events or otherwise.